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Glaucoma is one of the leading causes of blindness worldwide. Global prevalence 
has been estimated to be 3.54% and the total number of people with glaucoma was 
64.3 million in 2013 with a tendency to increase over the next decades. (1). In 
Germany, glaucoma affects approximately 972.000 people and is responsible for 
15% of all blindness, second only to age related macular degeneration (2). It 
represents an important burden for public health, making the development of an 
effective treatment essential for the future (2) (3). 
Glaucoma is characterized by a progressive loss of optic nerve fibres that results in 
visual impairment with a characteristic visual field loss. The exact mechanism in 
which this takes place is still not fully understood. However, increased intraocular 
pressure (IOP) is an important risk factor and it has been well documented that 
lowering the IOP is effective at preventing further progression of the disease (4). 
During the last century, an enormous effort has been put into finding an effective 
way to control the IOP in patients with glaucoma. Important advances in medical 
therapy have made the use of topically applied glaucoma medication the first-line 
option in the majority of the cases. Laser therapy, including Argon Laser 
Trabeculoplasty (ALT) and Selective Laser Trabeculoplasty (SLT) represent an 
effective alternative in some patients. However, a considerable portion of glaucoma 
patients still need incisional surgery in order to reach and maintain the desired IOP. 
Filtration glaucoma surgery and trabeculectomy have been the most widely used 
procedures. Nonetheless, the potential risk for postoperative complications, some 
of them vision threatening, limit the wide application of these techniques that are 
reserved for moderate to advanced cases of glaucoma (5). 
During the last years, a number of minimally invasive glaucoma surgical techniques 
(MIGS) have been developed in order to minimize the risk of surgery and reduce 
the IOP in glaucoma patients safely and effectively. MIGS share a number of key 
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characteristics that distinguish them from conventional glaucoma surgery. They are 
frequently performed ab interno through a clear corneal incision, thus sparing the 
conjunctiva. They are minimally traumatic and do not alter the ocular anatomy 
significantly. Recovery is generally fast and the need for postoperative care not as 
intense as in conventional filtration glaucoma surgery (6). 
MIGS encompass a variety of surgical techniques. Some of them use micro-stents 
that redirect aqueous flow (6) while others achieve similar results with the help of 
lasers (7) or specialized cutting instruments (8) that alter the physiologic outflow 
pathways of aqueous humour. The basic principles for reducing the IOP remain 
however the same as in classical glaucoma surgery. MIGS can therefore achieve 
IOP reduction either by improving trabecular outflow (9) or by redirecting aqueous 
into the subconjunctival or suprachoroidal space (6). 
Until now, the efficacy of MIGS procedures has been mainly assessed by the 
postoperative IOP values and the reduction in the number of IOP lowering 
medications that are needed postoperatively. Studies that examine the changes in 
aqueous dynamics in patients after MIGS surgery are limited. Given the abundance 
of different MIGS techniques and the lack of long-term studies, the development of 
an additional test that will examine the changes that occur in the outflow system of 
the eye after MIGS surgery will be able to better evaluate the IOP lowering potential 
of these procedures. It will also add to the understanding of how MIGS surgery 
works and will help in clinical decision making and future development of MIGS 
techniques. Recently, a new oculopressor device was developed in order to test the 
effectiveness of such MIGS procedures in a clinical setting (10). 
In this study the new oculopressor device was used to examine the efficacy of 
different MIGS techniques. The changes of IOP that occur after oculopression were 
measured in glaucoma patients who underwent MIGS surgery and were compared 
with the results of healthy individuals and glaucoma patients without previous 
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surgery. To our knowledge, this is the first clinical study that tests the efficacy of 
MIGS surgery using the new oculopressor and one of only few studies that assess 




























2.1. Anatomy and Physiology of the Eye 
In order to fully understand the intraocular changes that occur after MIGS surgery 
and how different MIGS procedures work, it is essential to be familiar with the normal 
anatomy and physiology of the human eye. In the next chapters, the basic concepts 
of ocular anatomy and physiology are explained with particular attention to aqueous 
humour, its production from ciliary body and outflow pathways, as well as the 
characteristic changes that occur in glaucoma. 
 
2.1.1. Gross Anatomy 
The human eye is located in the anterior part of the orbit and is held in position by 
six extraocular muscles, the superior, inferior, medial and lateral recti and superior 
and inferior oblique muscles. The walls of the orbit protect the eye from external 
injuries and provide attachment sites for the extraocular muscles while the 
connective tissue of the orbit offers additional support for the eye and the vascular 
and neural elements that enter and exit the globe (Figure 1). A thin layer of 
connective tissue, the fascia bulbi (Tenon’s capsule) covers the eye all the way from 
the optic nerve posteriorly to the corneoscleral junction anteriorly and separates it 
from the orbital fat (12). 
 
     
Figure 1: External anatomy of the eye and its relation with surrounding 
structures, the extraocular muscles and optic nerve (13) 
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The outer tunic of the eye consists of the sclera posteriorly and the transparent 
cornea anteriorly. The primary role of the sclera is to protect the intraocular 
structures and offer sufficient rigidity in order to maintain the shape of the eye. The 
cornea is part of the optical media and together with the lens offers sufficient 
refractive power in order to focus the light on the retina. 
The uveal tract is the middle or vascular tunic of the eye and consists of the choroid 
posteriorly and the ciliary body and iris anteriorly. The principal role of the choroid is 
to provide nutrients to the underlying retina. The ciliary body is an extension of the 
choroid anteriorly and serves a number of important functions including production 
of the aqueous humour, anchoring of the lens via suspensory ligaments and 
accommodation for near vision. The iris can be seen as a mobile diaphragm that 
separates the anterior and posterior chambers of the eye and regulates the amount 
of light that enters the eye. 
The crystalline lens of the eye is located behind the iris and is held in position by the 
suspensory ligaments (lens zonules) that anchor the lens to the ciliary body. 
Accommodation for near vision is achieved by contraction of the ciliary muscle 
releasing the tension of the lens zonules. 
The retina lies internal to the choroid and is the primary organ of vision. Posteriorly 
the axons of ganglion cells exit the globe by penetrating through the sclera and form 





Figure 2: Illustration of the internal anatomy of the human eye (14). 
 
The sclera is organized in three layers. The episclera is a thin superficial layer that 
connects the sclera to Tenon’s capsule. The middle part is called sclera proper and 
makes up more than 95 percent of its thickness, while the suprachoroidal lamina is 
a thin layer that connects the sclera to the underlying choroid. 
Along its surface, the sclera contains numerous openings and canals, some of them 
for blood vessels and nerves that enter and exit the eye. Most prominent of these 
are the anterior scleral foramen that is defined by the corneoscleral junction 
anteriorly and the posterior scleral foramen that supports the ganglion cell axons 
and blood vessels of the optic nerve. Several smaller openings are organized into 
emissary channels and vortex vein channels. 
The cornea is the transparent portion of the outer tunic of the eye and has a diameter 
of approximately 11.7 mm in the horizontal plane and 10.6 mm in the vertical plane 
in adults. It is organized in five layers, the corneal epithelium, Bowman’s layer, 
stroma, Descemet’s membrane and corneal endothelium. The corneal epithelium 
has a thickness of 50 µm and consists of stratified nonkeratinized epithelial cells 
organized in approximately 5-6 layers that lie on Bowman’s membrane. The corneal 
stroma constitutes approximately 90% of the corneal thickness. The uniform 
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organization of its collagen fibrils, in contrast to that of sclera, is responsible for the 
corneal transparency. The corneal endothelium consists of a single layer of cells 
that rest on Descemet’s membrane. Corneal thickness measures between 520 and 
670 µm, being thinnest centrally and thickest peripherally near the limbus. 
The transition between cornea and sclera at the corneoscleral junction, as well as 
the structures of the anterior chamber angle constitute an important anatomic 
location. The scleral sulcus, a notch on the inner surface of the sclera near this 
location, forms the external wall of Schlemm’s canal, the main outflow pathway for 
aqueous humour (12) (13) (14). 
 
2.1.2. The Ciliary Body and the Formation of Aqueous Humour 
The ciliary body was named by early anatomists after its unique resemblance to 
eyelashes or "cilia" and it has been a subject of research for centuries. It is part of 
the uveal tract and is positioned between the iris and choroid forming a slightly 
asymmetric girdle that encircles the eye. Its length varies, being broader temporally 
and inferiorly and shorter on the nasal side. In cross section it is triangular in shape 
with the base of the triangle facing anteriorly and the apex pointing to the opposite 
direction towards the choroid (Figure 3). On its anterior end the ciliary body is firmly 
attached to the scleral spur, while posteriorly it is only loosely attached to the sclera 
(13) (15). The iris inserts into the anterior surface of the ciliary body and in doing so, 
it leaves a small band of ciliary body tissue facing the anterior chamber that can be 
seen by gonioscopy between the root of the iris and scleral spur (4). The ciliary 
sulcus represents the anatomic region that is formed between the posterior surface 
of the iris and the most anterior ciliary processes. The ora serrata is the posterior 
end of the ciliary body. At this site the ciliary body epithelium ends abruptly and 
meets the retina.  
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The ciliary body can be divided morphologically and functionally into two parts. The 
anterior one third forms the pars plicata (or corona ciliaris) and is characterized by 
the presence of approximately 70-80 radially oriented ciliary processes with smaller 
ridges (minor plicae) in the valleys between them. The posterior two thirds have a 
smoother surface and constitute the pars plana (or orbiculus ciliaris). The pars plana 
and pars plicata of ciliary body are meridionally organized into ciliary process units. 
Each unit is made of a centrally located ciliary process that is bordered on each side 
by a pigmented ciliary ridge. (13) (16) (17). 
 
 
Figure 3: The ciliary body in cross section in relation to surrounding structures. 
Hematoxylin and Eosin (18). 
 
The zonular apparatus of the lens consists of zonular fibres arranged in bundles that 
extend from the pars plana of ciliary epithelium posteriorly to the lens capsule 
anteriorly. Throughout their course they are closely associated with the valleys of 
ciliary body, the ciliary processes and minor plicae, exhibiting varying degrees of 
attachment with them (Figure 4) (13). 
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Figure 4: Scanning electron microscopy of the ciliary body (CB), ciliary processes 
(CP), lens zonules (Z), lens (L), sclera (S) and Schlemm’s canal (SC) in 
cynomolgus monkey, x50 (19). 
 
Microscopically, the ciliary body is composed of ciliary muscle, vascular tissue, 
stroma and an overlying double-layered ciliary epithelium (13) (15). The epithelium 
of ciliary body is responsible for the formation of aqueous humour and has a unique 
architectural configuration, in which two epithelial monolayers are in direct apical-
to-apical apposition to each other (20) (21). This unique characteristic is the direct 
result of the infolding of optic vesicle that takes place during fetal development. The 
cells of ciliary body epithelium are extensively interconnected to each other with 
various junctional complexes suggesting that the two epithelial layers work together 
as a metabolic and functional unit (13) (20) (21). 
The ciliary muscle is described traditionally as having three distinct parts, the outer 
longitudinal fibres, the middle radial or reticular fibres and the inner circular fibres. 
All of the muscle fibres originate from the common ciliary tendon that is located in 
the region of scleral spur and trabecular meshwork (13) (15) (22). The ciliary muscle 
serves two important functions. Firstly, it enables accommodation of the lens for 
near vision and secondly, it regulates aqueous outflow through its effect on 
Schlemm's canal, trabecular meshwork and outflow system (Figure 5) (22) (23). 
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Figure 5: Ciliary muscle of monkey eyes treated with atropine (left) and 
pilocarpine (right). During contraction, ciliary muscle moves anterior and inward 
resulting in spreading of the trabecular meshwork lamellae and widening of the 
Schlemm's canal (24). 
 
The ciliary body and anterior part of the uvea, including the iris derive their blood 
supply from the anterior and long posterior ciliary arteries. The vasculature 
supplying these anterior parts of the uvea forms a system of anastomoses in three 
levels. At first, the anterior ciliary arteries branch extensively near the limbus to form 
the episcleral plexus. In addition, perforating branches from the anterior ciliary 
arteries, as well as branches from the long posterior ciliary arteries enter the ciliary 
muscle and form the intramuscular plexus. Finally, branches from both the anterior 
and long posterior ciliary arteries reach the root of the iris and together form the 
major arterial circle. Ciliary processes in primates are supplied from branches of the 
major arterial circle (25) (26). 
There is sufficient evidence from microvascular casting studies of primate eyes 
showing that the blood supply to ciliary processes consists of two separate systems. 
Anterior arterioles branch from the major arterial circle and supply the anterior parts 
and tips of the major ciliary processes. These arterioles show focal areas of 
constrictions before entering into the ciliary processes that may represent arteriolar 
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sphincters possibly regulating the blood flow to these areas that are responsible for 
aqueous humour production. On the other hand, the posterior arterioles that arise 
from the major arterial circle lack arteriolar constrictions, enter the major ciliary 
processes posteriorly to the anterior arterioles and are responsible for the blood 
supply of their middle and basal parts. Both anterior and posterior arterioles branch 
laterally to form interprocess capillary networks and ultimately drain into choroidal 
veins (Figure 6) (26) (27). 
 
   
Figure 6: Montage of ocular casting technique of cynomolgus monkey. On the 
left side, anterior ciliary arteries (ACA) arborize at the limbus and interconnect 
via lateral branches to form the episcleral circle (EC). On the right side the 
same eye as left with anterior ciliary arteries and ciliary muscle (CM) removed. 
Branches of perforating anterior ciliary arteries (PACA) and long posterior 
ciliary arteries (LPCA) interconnect to form the intramuscular circle (IMC). 
RCA, recurrent ciliary artery; CV choroidal veins. Magnification 20x (25). 
 
Until the early part of the 20th century, aqueous humour was thought to be a 
stagnant fluid that did not circulate. Since then, physiology of the aqueous humour 
production and outflow and its relationship with the development of glaucoma has 
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been a subject of intense research. It is now well known that aqueous humour is 
being continuously produced from the anterior parts of ciliary processes in the 
posterior chamber. It then follows a path from the posterior chamber into the anterior 
chamber passing through the pupil. In the anterior chamber, aqueous humour 
circulates under the effect of convection, flowing downwards near the cold cornea 
and upwards near the warmer iris. It finally exits the anterior chamber at the angle 
where it passes through the trabecular meshwork into Schlemm's canal and is 
ultimately drained into the aqueous channels and episcleral veins. A portion of 
aqueous humour exits the anterior chamber through a secondary "unconventional" 
uveoscleral pathway and it passes through the root of the iris and ciliary muscle into 
the suprachoroidal space (Figure 7). Aqueous humour serves a number of important 
functions in the eye including providing a clear fluid for optimal refraction of light, 
transport of nutrients and removal of waste products from avascular structures such 






Figure 7: Schematic representation of the primate anterior ocular segment. 
Arrows indicate aqueous humour flow pathways. Aqueous humour is formed by 
the ciliary processes, enters the posterior chamber, flows through the pupil into the 
anterior chamber and exits at the chamber angle via the trabecular and 
uveoscleral routes (28). 
 
The exact molecular mechanisms that take place during aqueous humour formation 
are until this day not entirely understood. The three main mechanisms that 
contribute to aqueous humour formation are diffusion, ultrafiltration and active 
secretion of ions and other molecules across the ciliary epithelium into the posterior 
chamber (28) (29). Ultrafiltration describes the passage of blood plasma through the 
highly fenestrated capillary endothelium of ciliary processes into the interstitial 
space between ciliary capillaries and ciliary epithelium. The main driving force of 
ultrafiltration is the osmotic and hydrostatic pressure gradients between capillaries 
and stroma. Diffusion occurs in parallel and describes the movement of molecules 
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down their concentration gradient. With the help of ultrafiltration and diffusion a 
"plasma reservoir" is accumulated in the stroma of ciliary processes between 
capillaries and ciliary epithelium. Further movement of this plasma reservoir into the 
posterior chamber is halted by the tight junctions between adjacent cells of the non-
pigmented ciliary epithelium. The ciliary epithelium is able to selectively transport a 
number of molecules and ions across this blood-aqueous barrier in an energy 
dependent manner generating an osmotic gradient. Water moves into the posterior 
chamber through specialized water channels in the ciliary epithelium called 
aquaporins or through a paracellular route down the osmotic gradient that is 
generated from the ion transport (30) (31) (32). During this process, cells of the non-
pigmented ciliary epithelium actively pump Na+ ions into the posterior chamber with 
the help of Na+/K+ ATPase. A number of other molecules and membrane 
transporters also contribute to this process including Na+/H+ antiports, Cl-/HCO3- 
antiports and Na-K-2Cl contransporters in the pigmented epithelium as well as the 
enzyme carbonic anhydrase that provides the needed HCO3- ions and regulates pH 
(Figure 8). The final composition of aqueous humour is therefore quite different from 
that of a simple plasma ultrafiltrate. It is characterized by a very low concentration 
of protein and relative higher concentration of ascorbate in relation to blood plasma. 
Moreover, it is slightly hypertonic and acidic with a pH of 7.2. Finally, exchange of 
substances between cornea, lens and neighboring structures gives aqueous 
humour its final composition. Lactate, for example, is found in slight excess in 
aqueous humour and may reflect the glycolytic activity of avascular structures such 





Figure 8: Overview of aqueous formation. Open circles with arrows: 
transporters/cotransporters/antiporters; arrows: movement via ionic channels or 
diffusion. Pa, extraocular arterial pressure; Ra, ciliary arterial resistance; BF, ciliary 
blood flow; Pc, ciliary capillary pressure; πc, capillary plasma oncotic pressure; Pt, 
stromal tissue hydrostatic pressure; πt, stromal tissue oncotic pressure; Pv, ciliary 
venous pressure; Rv, ciliary venous resistance; VO2, mitochondrial oxygen 
consumption; πa, aqueous oncotic pressure; F, aqueous flow; Ptd Ins, 
phosphatydalinositol; G, G-protein complex; R, receptor; C, adenylate cyclase; Gs, 
stimulatory G-protein complex; Gi, inhibitory G-protein complex; Rs, stimulatory 








Ultrafiltration and diffusion are responsible for approximately 10% of the aqueous 
humour production. The remainder 80-90% of aqueous humor formation is 
dependent on the active transport mechanisms that take place across the ciliary 
epithelium. The active part of aqueous humour secretion is pressure-insensitive and 
does not depend on the actual intraocular pressure when this is in the near-normal 
range. On the other hand, ultrafiltration depends on the pressure gradient that is 
present between the capillaries and posterior chamber. The rate of aqueous humour 
production in the human eye is approximately 2.5 - 2.75 µl/min and the aqueous 
humour turnover is estimated to be 1.0 - 1.5 percent of the aqueous humour volume 
per minute (29) (30) (31) (33). There is a marked diurnal variation of the rate of 
aqueous humour formation with higher rates during the day and lower rates during 
the night. The exact mechanism responsible for this circadian rhythm is not fully 
understood but several hypotheses have been proposed. Circulating epinephrine 
levels may play a role in regulating this circadian rhythm. Moreover, aqueous 
humour production is known to decrease with age, with an approximately 2 - 2.5% 
reduction per decade (31) (34) (35). 
 
2.1.3. Anterior Chamber Angle and the Outflow of Aqueous Humour 
The anterior chamber angle is formed by the root of the iris, a small band of ciliary 
body tissue, the trabecular meshwork and Schlemm's canal near the corneoscleral 
junction and constitutes the major route of aqueous humour outflow of the eye. 
During gonioscopy, the structures of the anterior chamber angle can be directly 
visualized and examined (Figure 9). The inner surface of sclera near the limbus has 
a small indentation, the scleral sulcus with a sharp posterior border called scleral 
spur and a smoother anterior end that reaches the inner surface of the cornea. The 
trabecular meshwork is a specialized three-dimensional structure that bridges the 
gap of the scleral sulcus and transforms it into a canal, the Schlemm's canal. At the 
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anterior end of trabecular meshwork, a pigmented line represents the transition to 
corneal endothelium and is called Schwalbe's line. The trabecular meshwork 
provides the necessary resistance to aqueous outflow that is needed, in order to 
maintain the intraocular pressure. In addition, the anterior tendons of ciliary muscle 
connect directly to different parts of the trabecular meshwork at the scleral spur (4) 
(15) (29). Contraction of the ciliary muscle has therefore a direct effect on the three-
dimensional arrangement of the trabecular meshwork lamellae and is able to 
change outflow resistance and facilitate aqueous humour outflow (24). 
 
 
Figure 9: Anterior chamber angle and gonioscopic findings. C, cornea; TM, 
trabecular meshwork; SS, scleral spur; CBB, ciliary body band; I, iris (4). 
 
The trabecular meshwork can be divided into three distinct parts based on its 
ultrastructural characteristics (Figure 10). The inner, lamellated part consists of the 
uveal and corneoscleral meshwork and the outer non-lamellated part consists of the 
juxtacanalicular meshwork. The uveal and corneoscleral parts of trabecular 
meshwork consist of irregularly arranged bands of extraceullular matrix covered by 
a monolayer of trabecular meshwork (TM) cells. On the other hand, the 
juxtacanalicular meshwork is made of a ground substance of extracellular matrix 
with several discontinuous layers of juxtacanalicular (JCT) cells resting on its 
18 
 
trabecular surface and embedded into it. The outer surface of juxtacanalicular 
meshwork faces the lumen of the Schlemm's canal and is covered by a continuous 
monolayer of endothelial cells. 
In addition, the anterior part of the trabecular meshwork that is directly behind the 
Schwalbe's line is only lightly pigmented and contributes little to the overall filtration 
of aqueous humour. On the other hand, the posterior part of trabecular meshwork 
is more heavily pigmented and is directly associated with the Schlemm's canal, 
providing the main route of aqueous humour outflow. 
Aqueous humour enters Schlemm's canal and is subsequently drained into a 
system of intrascleral aqueous channels that ultimately empty into the episcleral and 
conjunctival veins (Figure 11) (4) (24) (36) (37). 
 
   
Figure 10: Trabecular meshwork (TM) and outflow of aqueous humour. TM can be 
subdivided into an anterior non-filtering part (A) and a posterior filtering part (B) as 
well as into an inner lamellated part and a non-lamellated subendothelial or 
juxtacanalicular part. Aqueous humour leaves through the Schlemm's canal (1) 
and aqueous veins (2) or through a secondary "non-conventional" unveoscleral 




   
Figure 11: On the left side a scanning electron micrograph of the face of the uveal 
meshwork showing intersecting trabecular beams is illustrated. On the right, a 
schematic illustration of the aqueous outflow pathway from the Schlemm's canal to 
the episcleral vessels is shown (37). 
 
The movement of aqueous across the trabecular meshwork appears to occur in a 
passive, pressure dependent way that is driven by the hydrostatic pressure 
difference between the anterior chamber and the episcleral veins. However, the 
exact anatomic site responsible for the outflow resistance, as well as the actual 
mechanism by which aqueous crosses the juxtacanalicular trabecular meshwork 
remain unknown. 
The intertrabecular openings in the uveal and corneoscleral parts of trabecular 
meshwork seem to be too large to offer any resistance to outflow. According to 
dissection and microcapillary studies, it seems that the deepest 1/4 to 1/3 of the 
trabecular meshwork is the part offering the most resistance to outflow (36) (37). In 
particular, the extracellular matrix of juxtacanalicular meshwork appears to be 
responsible for a significant part of aqueous outflow resistance. A number of stimuli 
are able to influence outflow resistance by regulating extraceullular matrix 
degradation and turnover in the juxtacanalicular meshwork via enzymes of the 
metalloproteinase family. Finally, a number of histopathologic studies have 
20 
 
identified giant vacuoles and  pores in the inner wall cells of Schlemm's canal 
suggesting a paracellular route for aqueous humour outflow (36) (38) (39). 
In an effort to explain outflow resistance, some investigators proposed that flow of 
aqueous humour may exhibit a “funneling effect” that is the result of the anatomic 
relation between pores in the inner wall endothelium and juxtacanalicular tissue. In 
this way the “effective” resistance of the juxtacanalicular tissue would markedly 
increase (40). 
While the main bulk of aqueous humour leaves the eye through the ''trabecular'' 
outflow pathway, a secondary ''unconventional'' outflow pathway exists and includes 
the ciliary muscle and suprachoroidal space. A portion of aqueous humour enters 
the ciliary body from the anterior chamber traveling along the interstitial spaces of 
longitudinal fibres of the ciliary muscle and reaching the supraciliary and 
suprachoroidal spaces. From there a number of different arguments exist regarding 
the fate of aqueous humour. One theory suggests that aqueous passes through the 
sclera and episclera into the orbital tissue from where it is absorbed by the 
vasculature. This route is referred as the uveoscleral pathway. A second theory 
suggests that aqueous is absorbed from the choroidal vasculature and then reaches 
the vortex veins. This this route is called uveovortex pathway. It is difficult to 
calculate the proportion of aqueous humour that is removed by this secondary 
outflow pathway but it is estimated to be less than 10% of the total flow in adults and 
it decreases with age (37) (41). 
 
2.1.4. Intraocular Pressure and The Facility of Outflow 
In the healthy human eye, aqueous humour production and outflow are in 
equilibrium and the trabecular meshwork and uveoscleral outflow pathway provide 
the necessary resistance to outflow in order to maintain the intraocular pressure. 
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This relationship between aqueous humour production, outflow and intraocular 
pressure can be summarized by the following formula: 
 
Fin = Fout = (IOP – EVP)C + U 
 
Where Fin the rate of aqueous humour inflow or aqueous humour production and 
Fout the rate the aqueous humour outflow in µl/min; IOP the intraocular pressure and 
EVP the episcleral venous pressure in mmHg; C the facility of outflow in 
µl/min/mmHg and U the uveoscleral outflow rate in µl/min. The facility of outflow C 
can also be expressed as the reciprocal value of resistance to outflow R, where: 
 
C = 1/R 
 
In healthy humans, aqueous humour inflow (Fin) is approximately 2.5 - 2.75 µl/min, 
episcleral venous pressure (EVP) is about 9mmHg, outflow facility (C) 
approximately 0.25-0.3 µl/min/mmHg and the intraocular pressure is maintained at 
approximately 15mmHg. While trabecular outflow increases as the IOP raises in 
order to maintain the balance, the uveoscleral outflow remains fairly constant in the 
physiologic IOP range and seems to be independent of pressure (13) (29) (33). 
The distribution of intraocular pressure in the population resembles a Gaussian 
curve except for an elevation to the right side of the curve, possibly accounting for 
a subpopulation of people with an abnormally elevated intraocular pressure (Figure 
12). IOP increases with increasing age and there seems to be no relation between 
gender and IOP. Intraocular pressure follows a circadian rhythm. Most commonly, 
IOP is higher in the morning and drops to lower values in the evening. Other patterns 
of this diurnal rhythm of IOP can be encountered however in some individuals with 
peak IOP values in the afternoon or during the night. Fluctuations of the IOP of more 
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than 5mmHg are not common and wider oscillations may actually suggest the 
presence of glaucoma. Intraocular pressure is pulsatile following the arterial pulse 
and the cardiac cycle (4) (13) (28). Other factors influencing the IOP are postural 
changes and respiration, with an increase of IOP in the supine position and during 
a Valsalva maneuver (4) (42). 
 
   
Figure 12: On the left side a theoretical distribution of intraocular pressure in the 
population is shown. Note that the curve is slightly skewed to the right. This could 
be explained by two subpopulations. Group B would make up the normal 
population following the Gaussian curve and group C could represent the 
subpopulation with abnormally elevated IOP. On the right side a graphical 
representation of the normal diurnal variation of IOP (13). 
 
Measurement of IOP can be achieved with a variety of methods. Direct 
measurement is invasive, requires a manometer placed inside the eye and is 
possible to perform only in cadaver eyes or in animal studies. On the other hand, a 
number of techniques have been developed that can calculate the IOP by 
measuring the response of the eye to various types of mechanical deformation. The 
method that is used by these techniques is called tonometry and it can be further 
divided into applanation and indentation tonometry. With applanation tonometry a 
force is applied on the corneal surface until it is flattened. With knowing the force 
that is required to flatten or ''applanate'' a specific surface area of the cornea the 
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IOP can then be calculated. Applanation tonometers can be further subdivided into 
tonometers that use a fixed force and those that flatten a fixed area of the cornea 
with variable forces. One of the first applanation tonometers that were developed 
was the Maklakoff tonometer in 1855 that uses a fixed force technique. It was made 
of a metalic cylinder of known weight and a flat plate on its bottom that rested on the 
cornea. A special dye and anesthetic agent were applied on the eye and the 
tonometer was positioned on the cornea. The applanated area could then be 
measured from the bottom of the tonometer plate (13) (4). Fick developed a fixed 
area applanation tonometer in the late 19th century that was later improved by 
Goldmann and this has been the “gold standard” for IOP measurement since then 
(Figure 13, left). More recently, a non-contact tonometer using the same principle 
as the Goldmann applanation tonometer was introduced by Grolman in 1972 and 
uses an air column to applanate the corneal surface (13) (43) (44). 
The standard indentation tonometer was developed by Schiotz in 1905 and was 
widely used before the modernization of applanation tonometry by Goldmann. While 
applanation tonometers only flattens the corneal surface, indentation tonometers 
indent the cornea resulting in a considerable deformation of the eye and subsequent 
displacement of aqueous that raises the IOP to a new, higher value. With Schiotz 
tonometer the degree of indentation can be read on a scale on the tonometer and 
the IOP can be derived using conversion tables (Figure 13, right). Other types of 
tonometers that use both applanation and indentation principles include the Mackay-
Marg tonometer, the pneumatic tonometer and Tono-Pen (4) (13) (45). 
An induction-based, impact tonometer was developed by Kontiola in 2000 that is 
able to measure the IOP from calculating the rebound motion of a small probe that 
is propelled towards the corneal surface using magnets. The advantage of this 
technique is that it is fast, it requires no local anesthetic agent and it can be 
performed with the help of a small, handheld instrument with minimal patient 
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discomfort (46) (47). The overall reliability of rebound tonometry and its correlation 
with Goldman applanation tonometry has been found to be good making the new 
IOP measuring technique a good alternative to standard tonometry. Nonetheless, 
rebound tonometry tends to slightly overestimate IOP compared to standard 
applanation tonometry (48) (49) (50) (51). 
 
   
Figure 13: On the left photograph the technique of applanation tonometry using 
the Goldman tonometer and, on the right photograph the technique of indentation 
tonometry using the Schiotz tonometer (4). 
 
Tonometry, despite its importance in the everyday clinical practice and in the study 
of glaucoma, has its limitations. In indentation tonometry with the Schiotz tonometer, 
the degree of corneal indentation depends not only on the actual intraocular 
pressure, but also on the ocular rigidity and the distensibility of the ocular structures. 
For routine measurements, a normal ocular rigidity is assumed. This introduces 
however a substantial source of error in eyes with an abnormally high ocular rigidity 
(e.g. hyperopic eyes) or low ocular rigidity (e.g. myopic eyes), giving falsely high or 
low readings respectively. In Applanation tonometry, on the other hand, 
measurements are influenced by the corneal thickness (28). In rebound tonometry, 
IOP measurement seems to depend on the corneal thickness and biomechanical 
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properties of the cornea such as corneal hysteresis and corneal resistance factor 
(47) (50) (51). 
Clinically, the facility of outflow can be determined with the help of tonography. The 
tonographic principle was introduced by Grant in 1950 and was based on the 
observation that repeated Schiotz tonometry resulted in a decrease of the IOP. After 
placing the Schiotz tonometer on the patient’s eye, the IOP is raised resulting in an 
increase of trabecular outflow. If the Schiotz tonometer is left resting on the eye, an 
increasing amount of intraocular fluid will be forced out of the eye and the IOP will 
start to decline. Using an electronic Schiotz tonometer, Grant recorded the slope of 
falling IOP with the tonometer resting on the patient’s cornea (Figure 14) and with 
the help of Friedenwald’s observations on the volume and pressure relationships of 
the eye he calculated the outflow facility from the rate of IOP decline on the 
tonographic curve (52) (53). 
It was shown that glaucomatous eyes have a decreased facility of outflow and that 
the slope of the declining IOP during tonography was not as ‘’steep ‘’ as the one 
derived from healthy individuals. It was also shown that the primary reason of 
increased IOP in glaucomatous eyes was an increased resistance to aqueous 
outflow and not a hypersecretion of aqueous humour as it was previously falsely 
believed. As in indentation tonometry, the tonographic measurements are 
influenced by the ocular rigidity. Grant used for his mathematic formulas an average 
of ‘’normal’’ ocular rigidity. While quite accurate in most eyes, tonography should be 
performed with care in eyes with an abnormal rigidity as is the case in patients with 
high myopia. In addition, a number of ocular parameters change upon placing the 
tonometer on the eye, including ocular blood flow, the episcleral venous pressure 
and the rate of aqueous humour production, that are not taken into account in 
Grant’s mathematical formulations for calculating outflow facility (53) (54). 
26 
 
Another method that examines aqueous dynamics and the aqueous outflow system 
is Ulrich’s oculopression tonometry. Ulrich et al developed a new technique in 1987 
that used a suction cup placed on the conjunctiva that was able to raise the IOP to 
a predetermined level independent of the baseline IOP. The device was coupled to 
a slit lamp, so that the IOP could be directly measured using an applanation 
tonometer at any time during the oculopression (Figure 15). In his protocol, the IOP 
was raised to 45 mmHg and was maintained at this level for 8 minutes. He showed 
that the IOP after oculopression was significantly higher in glaucoma a patients in 
comparison to healthy individuals and proposed this new technique as an additional 
diagnostic test for assessing glaucoma suspects (55) (56). 
 
   
Figure 14: On the left side a tonographic unit and on the right side a tonographic 
curve showing the steady decline of IOP during tonography. Fine oscillations are 
due to IOP variations following the cardiac cycle while larger waves are the result 









Figure 15: Ulrich’s oculopression tonometry with the two suction cups coupled to a 
slit lamp and an applanation tonometer. The graph in the middle (a) is that of a 
healthy individual and the graph on the right side (b) that of a patient with open-
angle glaucoma. Note the difference in the IOP after oculopression (PR0) between 














2.2. Glaucoma: Basic Concepts in Diagnosis and Treatment 
2.2.1. Etiology and Classification of Glaucoma 
Glaucoma does not refer to a single disease entity. It rather comprises a larger group 
of ocular disorders sharing a set of characteristic abnormalities including cupping 
and atrophy of the optic nerve head that leads to progressive deterioration and loss 
of the visual field. In most but not all the cases there is a direct relation to an 
abnormally increased IOP. Classically, glaucoma has been divided into open-angle 
and angle-closure types. A third group of “developmental glaucoma” is associated 
with abnormal development of the anterior segment and aqueous outflow system 
and tends to appear earlier in life. Open-angle glaucoma can be further subdivided 
into a primary type or be caused by a secondary mechanism due to an underlying 
disorder. Angle-closure glaucoma can also be further characterized according to its 
clinical presentation as acute, subacute or chronic. The following table (Table 1) 




Primary open angle glaucoma (associated with high 
intraocular pressure) 
 
Low tension glaucoma (intraocular pressure within normal 
range) 
 
Secondary open angle glaucomas 
• Pseudoexfoliation glaucoma 
• Pigmentary dispersion glaucoma 
• Steroid induced glaucoma 
• Lens-induced glaucoma 
a. Phacolytic glaucoma 
b. Lens-particle glaucoma 
c. Phacoanaphylaxis 
• Glaucoma after cataract surgery 
a. α-Chymotrypsin glaucoma 
b. Glaucoma associated with viscoelastics 
c. Glaucoma associated with pigment dispersion 
and intraocular lens 
d. UGH syndrome (uveitis, glaucoma, hyphema) 
e. Glaucoma after Nd:YAG posterior capsulotomy 
• Posttraumatic glaucoma 
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• Glaucoma associated with intraocular hemorrhage 
a. Ghost cell glaucoma 
b. Hemolytic glaucoma 
c. Hemosiderosis 
• Glaucoma associated with retinal detachment 
• Glaucoma associated with uveitis 
a. Fuch’s heterochrmomic iridocyclitis 
b. Posner-Schlossman syndrome 
c. Uveitis associated with Herpes simplex or 
Herpes zoster 
• Glaucoma after vitreoretinal surgery (intraocular gas 
or silicone oil) 
• Glaucoma associated with an intraocular tumor 
• Amyloidosis 
• Glaucoma associated with increased episcleral 
venous pressure 
a. Superior vena cava obstruction 






• Pupillary block 
• Plateau iris 
• Phacomorphic block 
 
Secondary angle-closure 
• Neovascular glaucoma 
• Iridocorneal endothelial syndrome 
• Epithelial downgrowth 
• Fibrous ingrowth 
• Ciliary block 
• Suprachoroidal hemorrhage 




• Congenital glaucoma 
• Autosomal dominant juvenile glaucoma 
• Glaucoma associated with systemic abnormalities 
a. Chromosomal disorders 
b. Neurofibromatosis 
c. Oculocerebrorenal or hepatocerebrorenal 
syndrome 
d. Sturge-Weber syndrome 
e. Mucopolysachcharidosis 
• Glaucoma associated with ocular abnormaligies 
a. Axenfeld-Rieger syndrome 
b. Peters syndrome 
c. Aniridia 







• Posttraumatic glaucoma 
• Glaucoma associated with an intraocular neoplasm 
a. Retinoblastoma 
b. Leukemia 
• Glaucoma associated with uveitis 
• Lens-induced glaucoma 
a. Subluxation with pupillary block (Marfan 
syndrome, Homocysteinuria) 
b. Spherophakia with pupillary block 
• Glaucoma associated with congenital cataract 
surgery 
• Steroid induced glaucoma 
• Neovascular glaucoma 
a. Coat’s disease 
b. Familial exsudative vitreoretinopathy 
c. Retinoblastoma 
• Secondary angle-closure glaucoma 
a. Microphthalmos 
b. Nanophthalmos 
c. Retinopathy of prematurity 
d. Persistent hyperplastic primary vitreous 
e. Aniridia 
f. Iridoschisis 
g. Cornea plana 
• Glaucoma associated with increased episcleral 
venous pressure 
a. Idiopathic elevated episcleral venous pressure 
b. Orbital vascular malformations 
• Glaucoma secondary to intraocular infections 
a. Toxoplasmosis 
b. Herpetic iritis 
c. Congenital rubella 
 
Table 1: Classification of glaucoma (4) (28). 
 
Regardless of the type of glaucoma, the final common pathway is that of progressive 
loss of optic nerve fibres and resulting atrophy of the optic nerve head. This is 
clinically manifested with a characteristic pattern of visual field loss. The single most 
strongly associated risk factor with the presence of glaucoma is an increased IOP 
and it has been shown that lowering the IOP can substantially decrease the risk of 
disease progression. Other risk factors have also been identified. These include a 
positive family history, increasing age, myopia, diabetes mellitus and migraine. A 
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strong association between a glaucoma and a low diastolic ocular perfusion 
pressure (i.e. the difference between diastolic arterial blood pressure and intraocular 
pressure) has also been identified (4). 
 
2.2.2. Diagnosis of Glaucoma 
A wide variety of diagnostic tools have been developed in order for the 
ophthalmologist to be able to detect glaucomatous changes in their earliest stages, 
before advanced visual field loss has already taken place and when intervention 
with IOP lowering regimens would be most beneficial. 
The most basic of the examinations is the appearance of the optic nerve head during 
fundus examination with a dilated pupil (Figure 16). Characteristic glaucomatous 
changes of the optic nerve head include thinning and notching of the neural rim, 
deepening of the optic cup, exposure of the lamina cribrosa, splinter hemorrhages 
near the margin of the optic nerve head, appearance of vessels that bridge an 
enlarged optic cup, baring of the circumlinear vessels and nerve fibre layer defects. 
Special investigations with the help of confocal scanning laser tomography (HRT-III 
Heidelberg Engineering), confocal scanning laser polarimetry (Nerve Fiber Analyzer 
NFA-I) and spectral domain optical coherence tomography (SD-OCT) can deliver 
substantially more information regarding the anatomy of the optic nerve head, the 
thickness of the retinal nerve fibre layer (RNFL) and the configuration of optic 





Figure 16: On the left side a photograph of the optic disc of a patient with primary 
open-angle glaucoma and on the right side the same eye after a 12-year interval 
showing progression of the glaucomatous cupping and atrophy with concentric 
enlargement of the cup and focal thinning of the neural rim in the superotemporal 
quadrant (28). 
 
Functional examinations include visual acuity, visual field testing, color vision and 
contrast sensitivity. Visual field is a technique used to assess the central as well as 
the peripheral vision and measures the ability of the retina to distinguish a bright 
stimulus against a less illuminated background. Typical visual field defects for 
glaucoma include a generalized depression of the visual field, nasal step or 
depression, Seidel’s scotoma (i.e. enlargement of the blind spot in an arcuate 
manner) and isolated paracentral scotomata that may progressively enlarge and 
coalesce to form classic arcuate defects (Bjerrum scotomata). Advanced 
glaucomatous visual field defects can take the form of small central islands with or 
without sparing of the temporal visual field (28). 
 
2.2.3. Treatment of Glaucoma 
At present, the only proven method for delaying the progression of glaucomatous 
optic atrophy in patients with glaucoma is lowering the IOP. 
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Topically administered IOP-lowering agents can decrease the intraocular pressure 
by decreasing aqueous humour production or by increasing the rate of aqueous 
humour outflow. Currently there are five groups of locally administered antiglaucoma 
medications in clinical use. These include prostaglandin analogues, beta-receptor 
antagonists, carbonic anhydrase inhibitors, alpha-2 selective adrenergic agonists 
and parasympathomimetics. Systemically administered agents (carbonic anhydrase 
inhibitors and osmotics) are usually given only for a limited period of time when the 
IOP is very high and cannot be otherwise controlled and until a more definitive 
treatment can be planned, usually that being some kind of surgical intervention. 
Often the first line of therapy is a monotherapy involving a single topically 
administered IOP lowering medication. The IOP should be sufficiently reduced to a 
level in which the progression of glaucomatous visual field loss is kept to a minimum 
(4) (5).  
Although topical IOP-lowering medications are able to decrease the IOP 
substantially and in most cases sufficiently enough in order to halt the progression 
of the disease, an additional factor that must be taken into account is that of patient 
compliance and adherence to the treatment plan. In a systematic review of the 
literature, Reardon et al found that according to electronic monitoring more that 20% 
of the patients met criteria for poor compliance and according to prescription records 
only 31% of the patients had not discontinued their treatment at 12 months (57). In 
a more recent study, Rajurkar K et al found that among 151 glaucoma patients that 
were interviewed, 49% of them reported problems in using glaucoma medication, 
16% reported total non-compliance and 35% had an improper technique for 
administering the eye drops (58). The most common reasons for poor compliance 
and adherence to the treatment are complexity of the medication regimen, side 
effects, poor manual coordination, forgetfulness and cost of medication (59). In a 
recent study from Germany, Frech S et al found that the mean level of adherence 
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in terms of prescriptions filled was 66.5%. Risk groups for non-adherence were 
patients between the ages of 50 and 59, as well as patients older than 80 years, 
patients with a longer duration of glaucoma and patients with considerable 
comorbidity (60). 
Besides medical therapy, there are a number of alternative treatment modalities for 
glaucoma patients who need further IOP reduction or patients with poor compliance. 
Argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) are both 
effective and safe treatment options for lowering the IOP. Both ALT and SLT are 
performed at the slit lamp with the help of an argon or Nd:YAG laser and a Gonio-
lens. (5). ALT and SLT reduce the IOP by increasing trabecular outflow facility (61) 
(62) (63). Nonetheless, several studies showed that the IOP-lowering effect of both 
ALT and SLT wears off with time and that approximately half of the patients treated 
with either technique will have lost the IOP-lowering effect after 5 years (4) (5). 
Traditional glaucoma filtration surgery has the advantage of being able to decrease 
the IOP substantially for a long time in most patients and is being used in moderate 
to advanced glaucoma for optimal IOP control. However, the risk of postoperative 
complications, in some cases vision-threatening, has urged clinicians into searching 
for a better alternative. Non-penetrating glaucoma surgery techniques, including 
deep sclerectomy, viscocanalostomy and canaloplasty have the advantage of not 
entering the anterior chamber directly during surgery and thus minimizing the risk of 
postoperative complications such as hypotony, shallow anterior chamber, hyphema 
and choroidal effusions (4) (5) (64).  
During the last years a number of minimally invasive glaucoma surgical procedures 
have been developed that use small intraocular implants or laser energy in order to 
reduce the IOP to the desired level (6) (7). During the next paragraphs a number of 
these surgical procedures will be discussed. Finally, a new test based on a simplified 
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oculopression technique will be introduced for assessing the effectiveness of these 




























2.3. Microinvasive Glaucoma Surgery 
2.3.1. The iStent Inject System: A Trabecular Micro-Bypass Device 
The iStent inject (model GTS400) is a second-generation trabecular micro-bypass 
device that is implanted into the Schlemm’s canal in the nasal portion of the anterior 
chamber angle using an ab interno approach, clear corneal incision and a 
specialized injector system for the treatment of glaucoma. The implant is 360 µm in 
length, with a maximum width of 230 µm. It is cone-shaped and is made of heparin 
coated, gamma-sterilized titanium. The injector system is preloaded with two stents, 
so that it can deliver both of them without exiting the eye between the first and 
second implantation (Figure 17). After a successful implantation the stent is 
positioned with its flange residing in the anterior chamber, the thorax embedded in 
the trabecular meshwork and its head inside Schlemm’s canal (Figures 18 and 19). 
It has an inlet orifice on its one end facing the anterior chamber and four outflow 
openings on the opposite end that resides inside Schlemm’s canal. The device 










   
Figure 17: The G2-M-IS injector system is preloaded two GTS400 stents. The 
injector enters the eye with an anteriorly placed 23-gauge stainless steel insertion 
tube and delivers the stents into Schlemm’s canal after activation of the trigger 
mechanism by the surgeon. Normally two iStent inject devices are implanted into 
Schlemm’s canal at the nasal portion of anterior chamber angle, separated by 2-3 
clock hours (65). 
 
 
Figure 18: The GTS400 iStent inject device is a cone-shaped, heparin-coated, 
titanium micro-stent. It consists of a flange, thorax and a conical head. After 
implantation of the stent with the automated injector system the iStent inject is 
positioned with its flange facing the anterior chamber and the head residing inside 
Schlemm’s canal (66). 
 
Several studies have examined the efficacy and safety profile of iStent inject. 
Implantation can be performed either as a stand-alone operation or in combination 
with cataract surgery. The procedure has been shown to be safe with only few 
38 
 
postoperative adverse events, most of which are minor and not vision-threatening 
(6). In a large meta-analysis of 1767 eyes, the most common postoperative 
complications were elevation of the intraocular pressure, stent blockage or 
obstruction, stent malposition and hyphema (67). 
 
 
Figure 19: Two GTS400 stents gonioscopically visible after successful 
implantation in the anterior chamber angle (68). 
 
2.3.2. The XEN45 Gel Stent System: A Subconjunctival Micro-Stent 
XEN gel stent is a subconjunctival micro-stent designed for the treatment of 
glaucoma. It is a 6 mm long tube made of porcine collagen cross-linked with 
glutaraldehyde with a lumen diameter of 45 µm. The material of the stent has the 
distinctive ability to remain stiff when dehydrated while it softens upon contact with 
aqueous humour. The XEN gel stent is implanted into the subconjunctival space on 
the upper nasal part of the conjunctiva through an ab interno approach with clear 
corneal incision and the help of a specialized inserter device (Figure 20). The 
procedure can be performed as a stand-alone operation or in combination with 
cataract surgery. After the implantation a conjunctival filtering bleb is formed at the 
site of the stent that results from subconjunctival filtration of aqueous humour. The 
use of an antifibrotic agent is thus generally recommended to avoid scarring (6). 
Most commonly 0.1 ml of mitomycin C (MMC) 0.1 mg/ml is used, it is administered 
under the conjunctiva prior to stent implantation and not washed out (69) (70). After 
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correct placement of XEN gel stent, a small portion of it, approximately 1 mm, is 
visible in the anterior chamber, 2 mm are inside the scleral tunnel that is formed and 
3 mm are visible under the conjunctiva (71). 
 
 
Figure 20: Schematic representation of the XEN gel stent after successful 
implantation. A fistula is created connecting the anterior chamber with the 
subconjunctival space allowing for the filtration of aqueous humour through the 
stent lumen (72). 
 
2.3.3. Excimer Laser Trabculostomy 
Krasnov, in his original 1973 paper, was the first to describe the use of a Q-switched 
laser to produce “micropunctures” in the outflow region of anterior chamber angle 
for the treatment of open-angle glaucoma (Figure 21). In contrast to previous types 
of lasers, the Q-switched, modulated laser used by Krasnov was able to deliver a 
very large amount of energy in a short burst, thus eliminating the thermal and 
coagulative effects on tissues that were observed with previous types of lasers. The 
result was the formation of microscopic holes on the outflow region of anterior 
chamber angle with an improvement of outflow facility and drop of IOP. The new 
technique was named laseropuncture (73). While the technique described by 
Krasnov did not find widespread clinical use, it did open the way into the 
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development of other laser techniques that targeted the anterior chamber angle and 
the trabecular outflow pathway of the eye. 
 
   
Figure 21: Photograph of the Krasnov goniolens used in laseropuncture (left) and 
the original Q-switched laser unit adapted to a slit lamp (right) (73). 
 
Vogel et al developed a new surgical technique with the help of an excimer laser 
and published their first clinical findings in 1996 and 1997. The new laser could 
ablate the trabecular meshwork and remove the target tissue with only minimal 
thermal and coagulative damage. As a result, a new direct communication between 
the anterior chamber and Schlemm’s canal is achieved. The procedure is performed 
with an ab interno approach, small corneal incision and the help of a laser probe 
under gonioscopy (Figure 22). They documented an IOP lowering effect in 30 out of 
35 treated eyes with the new, minimally invasive technique (74) (75). Since then, 
other studies have also documented the IOP lowering effect of ELT either as stand-
alone operation or combined with cataract surgery and the procedure has been 





Figure 22: Surgical steps of an ab interno excimer laser trabeculostomy (ELT). 
First a paracentesis is performed in the superotemporal quadrant in peripheral 
cornea (upper left) and the anterior chamber is stabilized using a viscoelastic 
agent. The fibre-optic probe enters the anterior chamber and is advanced to 
contact the trabecular meshwork on the opposite side. The position of the laser 
probe is controlled endoscopically (upper right) or using a goniolens (lower left). 
Four to ten channels are created using the excimer laser. The laser probe is 
removed and the viscoelastic agent is washed out and replaced by balanced salt 
solution. Patent trabeculostomy channels are seen gonioscopically after the 












3. Materials and Methods 
In previous studies, success and failure of IOP lowering procedures, including 
minimally invasive glaucoma surgical techniques, has been mainly judged 
according to the postoperative IOP, change of IOP from preoperative baseline 
values or the number of glaucoma medications needed in order maintain the IOP at 
the desired level (6). However, IOP is only one of many parameters that define 
intraocular physiology and aqueous humour dynamics in the human eye. 
Tonography, first introduced by Grant and later further developed by Leydhecker, 
has been used to estimate the facility of aqueous outflow and distinguish between 
healthy individuals and patients with glaucoma in the past (52) (53) (54). Ulrich et al 
developed another technique for evaluating aqueous dynamics that eliminated 
several of the limitations encountered in classic tonography. They measured the fall 
of IOP that occurred after a period of oculopression using a suction cup coupled to 
an applanation tonometer in order to identify patients with glaucoma and named the 
technique oculopression tonometry (55) (56). With the development of newer 
techniques that are able to measure the IOP accurately and fast in the sitting 
position with minimal patient discomfort (43) (44) (46), as well as new high resolution 
imaging studies of the optic nerve head that can detect early glaucomatous changes 
(77) (78) (79), tonography and oculopression tonometry have become nowadays 
obsolete in the everyday clinical practice. 
This study attempts to investigate the changes of aqueous dynamics that occur after 
minimally invasive glaucoma surgery in order to better evaluate the efficacy and IOP 
lowering potential of different MIGS procedures. For this purpose, a newly 
developed oculopressor device was used (10). This device is a modification of the 
Taylor oculopressor and consists of a metallic cylinder weighing 60 g that moves 
freely inside a barrel-shaped plastic tube (Figure 23). During the oculopression, the 
foot of the metallic cylinder rests on the closed eyelid and exerts pressure on the 
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eye, raising the IOP at approximately 43mmHg (10). The examiner holds the device 
upright from its plastic part and the patient is asked to fixate at an object on the 
ceiling directly above him (Figure 24). 
  
 
Figure 23: The Taylor oculopressor (left) uses a metallic piston connected to two 
weights on each side. The new modified version (right) uses a similar metallic 
cylinder that is held upright inside a barrel shaped plastic tube. The IOP is 
measured using the iCare Tonometer. The result is a curve of IOP. P0 is the IOP 
at baseline before oculopression, PR0 the IOP directly after removal of the 











Figure 24: Measurement of the IOP with the iCare tonometer is followed by a 4-
minute long oculopression in the supine position. IOP is measured immediately 
after removal of the oculopressor and again 4 minutes later. 
 
Even though it is a new technique, the underlying theory is well established from 
previous works on tonography and oculopression tonometry (52) (53) (55). It is 
known, that upon placing the oculopressor on the eye the rate of aqueous outflow 
is artificially increased resulting in the displacement of a set amount of intraocular 
fluid. As a result, after removal of the oculopressor from the eye the IOP has fallen 
into a new, lower level. Eventually the IOP starts to rise again slowly until a steady 
state of aqueous humour production and outflow is achieved once again. The 
modified oculopression technique can therefore be regarded as a kind of “stress 
test” and the IOP reduction that occurs after oculopression reflects the overall 
outflow facility of the eye. 
In the study protocol IOP was first measured in the sitting position using the iCare 
tonometer. Oculopression was then performed on the study eye in the supine 
position for 4 minutes. The IOP was measured immediately after removal of the 
oculopressor from the eye and again 4 minutes later. The results can be outlined in 
a graph where P0 is the IOP at baseline, PR0 the IOP directly after removal of the 
oculopressor and PR4 the IOP after a recovery period of 4 minutes (Figure 23). 
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A 4-minute long oculopression has the advantage of being short enough in duration, 
in order to be able to examine patients routinely during consultation hours. It is also 
of sufficiently long duration, so that the IOP reduction that occurs can generate an 
IOP curve that can be measured accurately. 
In comparison to Ulrich’s oculopression tonometry, in which a repeated IOP 
measurement with the Goldmann applanation tonometer and the use of a suction 
cup placed on the conjunctiva is necessary for the measurements, the modified 
technique that we propose has the additional advantage of being more comfortable 
for the patients as no parts of the oculopession device come in direct contact with 
the cornea or conjunctiva during the test. 
Moreover, measurement of the IOP with the iCare tonometer is sufficiently fast and 
accurate and it can be easily performed immediately after the patient stands up from 
the supine position. 
Selection of patients was performed retrospectively after careful examination of 
patient files, diagnoses, previous surgeries and other ocular diseases from patient 
records. Exclusion criteria were extensive corneal scarring or previous corneal 
surgery that could otherwise influence an accurate IOP measurement with the iCare 
tonometer, ALT or SLT during the previous 3 years as well as previous filtration 
glaucoma surgery, as these procedures could have an impact on the oculopression 
curve that we measure and finally advanced glaucoma with considerable visual field 
loss. Most of the glaucoma patients that received a MIGS surgery between the years 
2015 and 2018 in the department of ophthalmology (Rostock University Medical 
Center) and were available for further screening were recruited in the study. An 
additional group of healthy individuals and a group of patients with glaucoma but 




All patients and healthy subjects underwent a thorough ophthalmological 
examination including examination of the anterior segment at the slit-lamp, fundus 
examination, gonioscopy (only in glaucoma patients) and documentation of local 
medication before and after the surgery, as well as documentation of any adverse 
events. Diagnosis and assessment of glaucoma was based on the funduscopic 
appearance of the optic nerve head and changes in the visual field, as well as 
findings in HRT (Heidelberg Retina Tomograph) and OCT (Optical Coherence 
Tomography) of the optic nerve head. All participants were asked to sign an 
informed consent before their participation in the study. 
Finally, a thorough statistical analysis of the results was performed using standard 
tests with SPSS software (Statistical Package for the Social Sciences) including 
descriptive statistics, one-sample Kolmogorov-Smirnov test for assessing test 
distribution, Kruskal-Wallis, Mann-Whitney and one-way ANOVA tests for further 

















Overall, 86 individuals were examined and divided into 5 different groups. All study 
subjects underwent IOP measurements and oculopression of the study eye 
according to the aforementioned protocol. The first group consisted of 38 healthy 
individuals between the ages of 23 and 81 (mean age was 36.9 ± 16.6 years) that 
had no history of previous ocular surgery or other eye disease. The second group 
consisted of 10 patients between the ages of 54 and 82 (mean age was 72.7 ± 8.8 
years) that were diagnosed with glaucoma and had no history of previous ocular 
surgery. Eight patients from the second group had a primary open-angle glaucoma, 
one patient had open-angle glaucoma secondary to pseudoexfoliation syndrome 
(PEX) and one patient had open-angle glaucoma secondary to pigment-dispersion. 
Groups 3, 4 and 5 consisted of 38 patients between the ages of 33 and 91 years 
(mean age was 70.4 ± 10.9 years) with different types of glaucoma and had 
previously undergone one of three different MIGS procedures (iStent inject 
implantation, XEN stent implantation and ELT). The procedures were performed 
either as stand-alone operations or combined with a cataract surgery. In group 3, 
19 patients with glaucoma had previously received an iStent inject implantation. In 
group 4, 14 patients had previously received a XEN stent implantation and in group 
5, 5 patients had undergone ELT (see Table 2). The average time interval between 
surgery and oculopression was 7.3 ± 5.9 months in group 3, 10.5 ± 11.0 months in 









Group Definition Number of 
individuals 
Age (range, mean 
± SD) in years 
1 Healthy individuals without previous 
ocular surgery or eye disease 
38 23-81, 36.9 ± 16.6 
2 Patients with diagnosed glaucoma 
without previous surgery 
10 54-82, 72.7 ± 8.8 
3 Patients with diagnosed glaucoma 
and previously performed iStent 
inject implantation (stand-alone or in 
combination with cataract surgery) 
19 57-85, 74.3 ± 7.1 
4 Patients with diagnosed glaucoma 
and previously performed XEN gel 
stent implantation (stand-alone or in 
combination with cataract surgery) 
14 55-91, 70.4 ± 9.3 
5 Patients with diagnosed glaucoma 
and previously performed ELT 
5 33-76, 55.6 ± 15.4 
 
Table 2: Definition of groups, number of individuals in each study group and 
corresponding range, mean and standard deviation (SD) of age in each of the 
groups. 
 
In most test subjects, the IOP curve that was obtained followed the same trend with 
an initial reduction of IOP after the 4-minute long oculopression and a gradual rise 





Figure 25: Oculopression curve in groups 1 through 5. Group 1 (Healthy 
individuals), Group 2 (Patients with diagnosed glaucoma without previous 
surgery), Group 3 (Patients after iStent inject implantation), Group 4 (Patients after 
XEN gel stent implantation), Group 5 (Patients after ELT). 
 
By calculating the Spearman’s rank correlation coefficient, a statistically significant 
correlation (p<0.05) between the baseline IOP (P0) and the degree of IOP reduction 
that occurred after oculopression (PR0-P0) was found in groups 1 through 4. 
Generally, patients with higher baseline IOP had a more pronounced reduction of 
IOP after oculopression. In order to eliminate this problem and be able to assess 
the “oculopressive” effect independently, we introduced an additional parameter and 
calculated the percentage of IOP reduction in relation to baseline IOP with the 
following formula: 
IOP Reduction (percentage) = [(PR0-P0)/P0]x100 % 
P0 PR0 PR4
Group 1 16,2 9,7 12,1
Group 2 15,2 10,3 12,7
Group 3 15,2 9,4 11,4
Group 4 12,6 7,2 10,1















Oculopression curve in groups 1 through 5
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Mean baseline IOP was 16.2 ± 3.6mmHg in group 1 (healthy individuals) and 
decreased to 9.7 ± 3.0mmHg after oculopression representing a 40.7 ± 11.8% drop 
from baseline. In the recovery phase IOP increased to 12.1 ± 3.7mmHg. In group 2 
(patients with glaucoma and without previous surgery) mean IOP at baseline was 
15.2 ± 5.8mmHg under local medication, it decreased to 10.3 ± 5.0mmHg after 
oculopression, representing a 34.3 ± 9.5% drop and increased again after the 
recovery period to 12.7 ± 5.2mmHg. Patients after implantation of iStent inject 
(group 3) had postoperatively a mean IOP of 15.2 ± 4.3mmHg at baseline. IOP 
dropped to 9.4 ± 2.7mmHg after oculopression, representing a 36.5 ± 14.0% 
decrease from baseline and rose again to 11.4 ± 2.9mmHg after the recovery phase. 
Patients after implantation of XEN stent (group 4) had the lowest mean IOP at 
baseline with 12.6 ± 2.9mmHg. IOP decreased after oculopression to 7.2 ± 
2.0mmHg, the lowest IOP after oculopression in all of the groups, representing a 
42.8 ± 10.2% drop from baseline and increased again after the recovery phase to 
10.1 ± 3.6mmHg. Group 5 (glaucoma patients after ELT) had a mean IOP of 16.8 ± 
6.5mmHg at baseline, the highest among all groups. It decreased after 
oculopression to 13.2 ± 7.0mmHg representing only a 25.7 ± 13.9% drop. It then 
rose again to 14.4 ± 6.0mmHg after the recovery period (Figures 25, 26 and 27). 
The change of IOP in respect to baseline values is graphically depicted in Figure 
28. During the recovery phase mean IOP increased in all groups but did not reach 
the initial IOP values in any of the studied groups. 
The IOP reduction after oculopression (PR0-P0) was statistically significantly lower 
(p=0.021) in group 2 (patients with glaucoma and without previous surgery) in 
comparison to group 1 (healthy individuals). PR0-P0 did not differ significantly in 
patients after iStent implantation (group 3) or XEN Stent implantation (group 4) in 




Figure 26: The fall of IOP immediately after oculopression (PR0-P0) in absolute 
values in groups 1 through 5. 
 
 
Figure 27: The fall of IOP immediately after oculopression [(PR0-P0)/P0] in 
percentage in groups 1 through 5. 

































IOP decrease after Oculopression














































Figure 28: The change of IOP in relation to baseline IOP during the oculopression 
test in groups 1 through 5 (Average values). 
 
The mean number of different IOP lowering medications was 2.5 ± 1.3 in the group 
of glaucoma patients without previous operations (group 2). In glaucoma patients 
after XEN stent or iStent inject implantation (groups 3 and 4) the number of IOP 
lowering medications that were needed was statistically significantly lower in 
comparison to group 2 (p=0.006 and p=0.01 respectively) (Figure 29). Patients after 
implantation of XEN gel stent (group 4) needed the least amount of medications 
(n=0.4 ± 0.9), followed by patients after iStent inject implantation (n=0.8 ± 1.4) and 
patients after ELT (n=1.6 ± 0.9). Only 6 out of 19 patients after iStent inject and 2 
out of 14 patients after XEN stent implantation needed further IOP reduction using 













Change of IOP from Baseline during the Oculopression Test in Groups  
1-5 (Average Values)
Group 1 (n=38) Healthy individuals
Group 2 (n=10) Glaucoma patients without surgery
Group 3 (n=19) iStent Inject
Group 4 (n=14) XEN Stent
Group 5 (n=5) ELT
53 
 
received an ELT could discontinue the antiglaucoma medication postoperatively 
(Figure 30). It is important to notice that what was documented here was the number 
of different medication classes that the patient was using and not the number of 
daily applications. For example, if a patient had a beta-blocker agent in his 
medication plan that was applied two times per day, the number of IOP lowering 
medications was 1, even though he had to take the same eye drops twice, in the 
morning and in the evening. 
 
 
Figure 29: Mean number of antiglaucoma medications used at the time of the 




































Figure 30: Number of patients that needed further IOP reduction with topical 
medication (orange) and medication free patients (blue) after MIGS surgery. 
 
The age of test subjects did not show any consistent correlations neither with 
baseline IOP nor with the IOP decrease after oculopression in the examined 
population. 
Due to the nature of the operation, a considerable portion of patients after 
implantation of XEN stent had to come for surgical revision and needling of the 
filtering bleb due to conjunctival scarring in our clinic. Five out of the 14 patients that 
were included in the study had at some point received a surgical revision with 
needling of the filtering bleb and one of these 5 patients had undergone needling 
three times by the time of the study. The needling rate was thus calculated to be 




















Several studies have assessed the IOP lowering effect of MIGS surgical techniques 
in the past. In this chapter we will first discuss some of the similarities between those 
studies and our findings. We will then describe in which way our approach differs 
from that of previous studies and how our findings contribute to the overall 
understanding of how MIGS surgery works. Finally, we will try to explain the 
advantages that microinvasive surgical techniques offer in modern glaucoma 
surgery but at the same time define their limitations as well. 
With some exceptions, our results generally follow the same trend seen in published 
literature. Regarding the older techniques, the oculopression curves that were 
obtained in our study were similar to that of tonography and oculopression 
tonometry, which also produce a gradual IOP reduction after a force is applied on 
the eye surface (in the case of tonography) or when the IOP is artificially increased 
using suction cups placed on the conjunctiva (in the case of oculopression 
tonometry) (52) (55). This finding supports the theoretical basis of our study and 
confirms our hypothesis, that our technique can be regarded as a kind of “stress 
test” that reflects the outflow facility of the eye (IOP reduction in the first part of the 
oculopression curve) and the physiologic return to the steady state (rise of IOP in 
the second part of the oculopression curve during the recovery period). 
As far as baseline IOP after MIGS surgery is concerned, our measurements agree 
with the results of previous studies in several instances. We found a mean IOP of 
15.2 ± 4.3mmHg after iStent inject implantation. In several studies mean IOP after 
implantation of iStent inject has been documented to be in the range between 13.0 
and 16.25mmHg (6) (66) (80) (81). 
Arriola-Villalobos et al evaluated the efficacy and safety of iStent inject combined 
with phacoemulsification in 20 patients with a mean follow up of 47.40 ± 18.46 
months. Mean IOP at baseline was 19.95 ± 3.71mmHg under medication and 26.0 
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± 3.11mmHg after medication washout. At the end of the follow up period mean IOP 
was 16.25 ± 1.99mmHg with a 36.92% decrease from baseline IOP (80). Voskanyan 
et al examined 99 patients with open-angle glaucoma that underwent implantation 
of two GTS400 stents over a period of 12 months. Mean IOP at screening was 22.1 
± 3.3mmHg under medication and 26.3 ± 3.5mmHg after medication washout. At 
month 12, mean IOP was 15.7 ± 3.7mmHg representing a 39.7% decline from 
baseline IOP (66). In a more recent study, Clement et al evaluated the safety and 
efficacy of iStent inject combined with cataract surgery in a retrospective study of 
165 eyes of patients with various types of glaucoma or ocular hypertension. They 
found that mean IOP decreased significantly from 18.27 ± 5.41mmHg at baseline to 
14.04 ± 2.98mmHg at month 12, which equals a 23.2% reduction (81). Best et al 
investigated the efficacy of iStent inject in combination with cataract surgery in a 
prospective, randomized, simple-blind study. They examined 65 eyes from 56 
patients with primary open-angle glaucoma, 31 of which underwent a combined 
cataract surgery with implantation of two GTS400 stents and 34 of which underwent 
cataract surgery without stent implantation. Mean follow-up time was 14 months. 
Patients that received the combined surgery showed a mean IOP reduction of 
5.9mmHg or 23.5% from baseline while patients that received cataract surgery 
alone showed a mean IOP reduction of 2.1mmHg or 9.5% from baseline (68). In 
another study, Klamann et al evaluated 35 patients with open-angle glaucoma that 
received two GTS400 stents. They found an average IOP decrease of 33% from 
baseline at 6 months (82). All studies found a significant reduction of antiglaucoma 
medication postoperatively (66) (68) (80) (81) (82). 
Nevertheless, in our test we do not simply measure the IOP postoperatively. The 
oculopression test in our study is a dynamic measurement and the IOP reduction 
that occurs (PR0-P0) in the first part of the test reflects the outflow facility of the eye. 
In patients after iStent inject implantation (group 3) we found a more pronounced 
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IOP reduction after oculopression in relation to non-operated glaucoma patients 
(group 2). it can therefore be suggested that iStent inject implantation had a positive 
effect on aqueous outflow facility. 
Currently there are only few studies that measure aqueous dynamics in patients 
after MIGS surgery. A study from Fernández-Barrientos et al measured the changes 
in aqueous humour dynamics using fluorophotometry in a group of 33 patients with 
open-angle glaucoma or ocular hypertension scheduled to receive cataract surgery 
with or without implantation of iStent (first generation implant). In both groups 
aqueous flow (F) was similar before surgery and did not change postoperatively. 
Trabecular outflow facility (Ct) however increased in both groups. In the first group 
that received cataract surgery with iStent, Ct increased by 275% to 0.45 ± 0.27 
µl/min/mmHg while in the second group that received cataract surgery alone Ct 
increased by 46% to 0.19 ± 0.05 µl/min/mmHg (11). 
The results from Fernández-Barrientos et al agree in this regard with the findings in 
our study. Though not measuring the outflow facility directly, our test also assesses 
the aqueous outflow system. 
Nonetheless, fluorophotometry and oculopression tonometry are inherently different 
methods for assessing aqueous humour dynamics. The main difference lies in the 
fact that in oculopression techniques an external force is applied on the surface of 
the eye. The intraocular changes that occur in response to this external force are 
then measured using tonometry. On the other hand, studies of aqueous dynamics 
that use the principle of fluorophotometry measure aqueous flow without altering the 
physiologic steady state of the eye. 
Patients after XEN stent implantation had a considerably lower IOP at baseline in 
our study compared to previous studies in the published literature. Baseline mean 
IOP was 12.6 ± 2.9mmHg in our study and it has been documented to be between 
14.8 and 17.1mmHg in several other studies (6) (69) (71) (83). This could be in part 
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explained by the low target IOP in the selected patients and the tendency of 
relatively prompt intervention (e.g. Needling or surgical revision of the filtering bleb) 
in patients where the IOP increased above the desired level in our clinic.  
In our study, patients after XEN stent implantation demonstrated a large reduction 
of IOP after oculopression (PR0-P0) and in percentage values, they had the largest 
IOP reduction among all groups, even in comparison to healthy individuals (IOP 
reduction after oculopression was -40.7 ± 11.8% in healthy individuals and -42.8 ± 
10.2% in the XEN stent group). In addition, the lowest value among all IOP 
measurements was 7.2 ± 2.0mmHg, the mean IOP directly after oculopression in 
the XEN stent group.  
Previous studies have documented the IOP lowering efficacy of XEN get stent. 
Reitsamer et al evaluated 218 eyes of 199 patients with moderate primary open-
angle glaucoma that received a XEN gel stent with or without concomitant cataract 
surgery. The follow up time was 24 months. Mean IOP was reduced from 21.4 ± 
3.6mmHg at baseline to 14.9 ± 4.5mmHg at month 12 (representing a -29.3% 
reduction) and 15.2 ± 4.2mmHg at month 24 (representing a -27.8% reduction), 
while the number of IOP lowering medications was decreased from 2.7 ± 0.9 at 
baseline to 0.9 ± 1.1 and 1.1 ± 1.2 at month 12 and 24 respectively. Needling rate 
was documented to be 41.1% and mean number of needling procedures was 1.6 ± 
1.1 at 24 months (71). In another study from Smith et al, 1-year outcomes after XEN 
gel stent implantation in 68 patients with glaucoma were evaluated. Mean IOP 
decreased from 22.1mmHg at baseline to 14.8mmHg at 12 months, representing a 
33% reduction. Mean number of IOP lowering medications reduced from 2.9 at 
baseline to 1.1 at 12 months. Revision or needling of the subconjunctival bleb was 
necessary in 30 patients (44.1%) and 15 patients (22.1%) developed a significant 
perioperative or postoperative complication, including hyphema (n=6), iris prolapse 
(n=1), hypotony (n=5), choroidal effusions (n=1), tube exposure requiring surgical 
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revision (n=1) and hypotony with severe choroidal effusion (n=1) (83). In a 
retrospective study, Heidinger et al evaluated 199 eyes from 160 patients that 
received a XEN gel stent from 2014 to 2016. They found that mean IOP decreased 
from 22.8 ± 6.9mmHg at baseline to 17.1 ± 6.1 mmHg, 17.1 ± 5.9mmHg and 16.4 ± 
3.8mmHg after 1, 12 and 18 months. Mean number of medications was also 
reduced from 2.9 ± 1.0 at baseline to 1.8 ± 1.4 after one year (69). 
Our findings, as well as the results from previously published studies that 
investigated the efficacy of XEN gel stent indicate that the subconjunctival filtering 
pathway can be very effective at lowering the IOP, and possibly more effective than 
interventions that target the trabecular outflow (i.e. iStent inject or ELT). 
The subconjunctival filtering pathway that is created during XEN gel stent surgery is 
however a “non-physiologic” state for the human eye, in that normally the aqueous 
humour does not reach the subconjunctival spaces. Subconjunctival filtration is the 
principle that is also used in some of the more invasive glaucoma surgeries, such 
as trabeculectomy (4). The drawback in all of these surgical techniques is the 
possibility of conjunctival scarring and resulting bleb failure. Patients must therefore 
be informed of the potential risks that are associated with every filtering procedure 
that result in the formation of a subconjunctival bleb, including that of XEN gel stent 
as well as the necessity of an intensive postoperative care and the relatively high 
probability of needling or surgical revision (69) (4). 
As mentioned above, we found a needling rate of 35% in our patients after XEN gel 
stent implantation. The results are comparable to the aforementioned studies from 
Reitsamer et al (41.1% needling rate) and Smith et al (44.1% needling rate). 
However, due to the exclusion criteria that we used; patients that had to undergo a 
different kind of surgery due to stent failure (e.g. trabeculectomy) were not included 
into our calculations. It is therefore safe to assume that the complication and revision 
rate were actually higher than the numbers our data show. 
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Interestingly, ELT has not been able to achieve the same level of IOP reduction as 
iStent inject or XEN stent in our study. We found a baseline mean IOP after ELT of 
16.8 ± 6.5mmHg. This agrees in part with observations in previous studies, where 
IOP was between 16.5mmHg and 19.6mmHg after ELT, considerably higher than 
the IOP after iStent inject or XEN stent (7) (84) (85). 
ELT patients also exhibited the lowest IOP reduction after oculopression in our study 
with -3.6 ± 0.9mmHg in absolute values and -25.7 ± 13.9% reduction in regard to 
baseline IOP. However, with only 5 patients in the ELT group, further conclusions 
are difficult to be made at this point due to the low number of participants. 
Current literature regarding ELT is limited. A number of studies have examined 
however the IOP lowering effect after ELT. Pache et al examined 135 patients with 
open-angle glaucoma or ocular hypertension that received ELT as stand-alone 
procedure or combined with cataract surgery. The two groups were further 
subdivided according to baseline IOP (group 1 when IOP was ≥ 22mmHg and group 
2 when IOP was ≤ 22mmHg). In the group that received ELT without cataract 
surgery, mean IOP decreased from 27.9 ± 3.9mmHg to 19.3 ± 5.5mmHg after 1 
year when baseline IOP was ≥ 22mmHg and from 20.2 ± 1.1mmHg to 17.6 ± 
3.3mmHg when baseline IOP was ≤ 22mmHg. In the second group that received 
ELT combined with cataract surgery, mean IOP decreased from 26.4 ± 2.75mmHg 
to 16.7 ± 2.75mmHg after 1 year when baseline IOP was ≥ 22mmHg and from 19.6 
± 1.1mmHg to 16.3 ± 2.2mmHg when baseline IOP was ≤ 22mmHg (7). Töteberg et 
al evaluated 24 eyes of 24 patients with cataract and open-angle glaucoma or ocular 
hypertension that received a combined operation of ELT with phacoemulsification 
and intracapsular lens implantation. The follow up time was 12 months. Mean best 
corrected visual acuity (BVCA) increased from 0.45 ± 0.25 at baseline to 0.78 ± 0.30 
at 12 months while mean IOP decreased from 25.33 ± 2.85mmHg to 16.54 ± 
4.95mmHg representing a 34.70% reduction. Mean number of IOP lowering 
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medications decreased from 2.25 ± 1.26 to 1.46 ± 1.38 at 12 months (84). Another 
study from Babighian et al examined the efficacy and safety of ELT in 21 eyes from 
21 patients with primary open-angle glaucoma. They found that mean IOP 
decreased from 24.8 ± 2.0mmHg at baseline to 16.9 ± 2.1mmHg after a mean follow-
up of 25.3 ± 1.3 months corresponding to a 31.8% reduction. Mean number of IOP 
lowering medications also decreased from 2.24 ± 0.6 to 0.71 ± 0.8 (85). 
In our study, we documented a significant reduction in the amount of IOP lowering 
medications in patients after iStent and XEN stent surgery. Mean number of 
antiglaucoma medications was 0.8 ± 1.4 after iStent inject and 0.4 ± 0.9 after XEN 
stent implantation. Patients after ELT still needed fewer medications compared to 
non-operated glaucoma patients (1.6 ± 0.9 versus 2.5 ± 1.3) but the number of 
antiglaucoma medications that they needed was considerably higher than iStent and 
XEN stent patients. Our results agree with the results of previous studies that have 
examined MIGS techniques and have also found a significant decrease of 
antiglaucoma medications postoperatively (6) (7) (66) (69). 
To conclude, it is important to keep in consideration that, compared to the 
aforementioned studies in most cases of which the preoperative – postoperative 
IOP reduction after MIGS surgery was simply calculated, we measured the IOP 
reduction that occurred after oculopression postoperatively. In this regard, our test 
measures something fundamentally different from that in previous studies and 
therefore it cannot be directly compared with them. In our opinion, our test 
introduces an important new parameter that describes not only the current IOP but 
offers some additional information regarding the status of aqueous outflow system 
and intraocular physiology. Many researchers have been examining these 
physiological events since decades. It is however the simplicity of the modified 
oculopressor technique and the ease of use of rebound tonometry that enabled us 
to carry out such an examination in a clinical setting in patients after MIGS surgery. 
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In our study, the most important parameters were the IOP reduction that occurred 
after oculopression (calculated in absolute values, PR0-P0 and also in relation to 
the baseline IOP, [PR0-P0]/P0x100%). Both measurements differed among the 
studied groups as seen in figures 26 and 27 and in regard to PR0-P0, healthy 
individuals showed a significantly larger reduction of IOP after oculopression 
compared to non-operated patients with glaucoma (-6.6 ± 2.1mmHg reduction in 
healthy individuals versus -4.9 ± 1.6mmHg reduction in non-operated glaucoma 
patients). This agrees with older observations with tonography and oculopression 
tonometry that also show a distinctive difference in outflow facility between healthy 
individuals and patients with glaucoma (53) (54) (55). The oculopression curves of 
patients after XEN stent and iStent inject implantation were different compared to 
non-operated glaucoma patients and their results approximated those of healthy 
individuals. This suggests that the intraocular implants positively influenced 
aqueous outflow and that they had a “corrective” effect on the oculopression curve 
in the selected patients. However, a direct comparison between the different MIGS 
procedures is not possible at this point, as the number of the examined patients is 
limited. Moreover, in future studies preoperative as well as postoperative 
measurements with the oculopression test in patients that are scheduled to receive 
a MIGS surgery should be carried out in order to better examine the effect that these 
procedures have on aqueous outflow. 
Nonetheless, based on our findings we can still make some additional observations 
regarding MIGS techniques. In our study, the trabecular approaches that we 
examined (ELT and iStent inject implantation) were considerably simpler, safer and 
less invasive compared to the subconjunctival approach used during XEN stent 
implantation. This is also evident in the number of postoperative complications and 
number of surgical revisions needed (35% needling rate after XEN Stent 
implantation). However, patients after XEN stent implantation benefitted from lower 
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IOP values postoperatively. Apparently, there is a kind of trade-off between the 
“invasiveness” of a glaucoma surgery and its IOP lowering effect that needs to be 
considered during clinical decision making. In general, we could say that the more 
invasive an operation is, the greater its IOP lowering effect. With MIGS, the 
glaucoma surgeon tries to achieve the best postoperative IOP, while keeping a low 
complication profile. During the last years, MIGS surgery has revolutionized the way 
decision making is being made when considering IOP reduction in glaucoma 
patients. More patients are operated early in the disease course in order to prevent 
side effects of local medication or reduce the amount of eye drops a patient may 
need. More invasive glaucoma surgeries like trabeculectomy and other incisional 
techniques are nowadays reserved for more advanced cases of glaucoma, where 
other approaches have failed. A substantial number of patients could thus benefit 
from such microinvasive glaucoma surgeries, postponing or even avoiding some of 
the more invasive procedures. 
The best surgical technique that will achieve a substantial and long-lasting IOP 
reduction with minimal complications is still to be found. It is our belief, that the newly 
introduced oculopression technique will have an important place in the assessment 
of current glaucoma surgical techniques and in the development of new MIGS 
surgical techniques in the future. As more intraocular implants and MIGS techniques 
are being developed, more reliable parameters that can assess the IOP lowering 
potential of these procedures are needed, and the new oculopression technique 
could be one of them. However, a larger number of patients will have to be 
examined, in order to detect differences between individual surgical techniques. 
We hope, that the oculopression technique that we introduced, will be able to help 






Glaucoma is one of the most common causes of blindness worldwide. The only 
evidence-based treatment to slow down the progression of glaucoma is the 
reduction of intraocular pressure (IOP) using local medication or through surgery. 
During the last years, a large number of microinvasive glaucoma surgery techniques 
(MIGS) have been developed, in order to reduce the IOP in glaucoma patients safely 
and effectively. Until now, efficacy of MIGS has been assessed mainly according to 
the postoperative IOP and the number of medications used. Results from long-term 
studies are rare or currently not available in the majority of the cases. In order to 
better evaluate the functionality of MIGS, a new examination method has been 
developed with the help of a new oculopressor device. In this study the efficacy of 
different MIGS techniques was examined using the new oculopressor. 
At first, glaucoma patients that had previously received a MIGS surgery (iStent 
inject, XEN Stent, ELT) were examined with the new oculopression test. Their 
results were compared with those of non-operated patients and healthy individuals. 
Overall, 38 healthy subjects (group 1), 10 non-operated patients (group 2), 19 
patients after iStent inject implantation (group 3), 14 patients after XEN Stent 
implantation (group 4) and 5 patients after ELT (group 5) were examined. The new 
examination measures the reduction of IOP that occurs after oculopression and can 
be seen as an indirect measurement of the outflow facility of the eye. 
The IOP-reduction after oculopression differed among the study groups. Non-
operated patients showed a significantly lower IOP-reduction compared to healthy 
individuals. Patients after iStent inject and XEN stent implantation showed a larger 
reduction of IOP after oculopression in relation to non-operated patients and their 
results approximated those of healthy individuals. These patients needed fewer 
medications postoperatively in relation to non-operated patients. Patients after ELT 
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showed postoperatively a smaller reduction of IOP after oculopression compared to 
iStent inject and XEN stent patients. 
MIGS can increase the outflow facility of the eye in patients with glaucoma. Though 
ELT had the lowest impact on the aqueous outflow among the studied procedures 
in this study. The new test can help in the evaluation of current and further 
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• A new oculopression technique was successfully used in a 
clinical setting for assessing the efficacy of microinvasive 
glaucoma surgery. 
 
• Most of the examined subjects showed an initial decrease of 
IOP after the 4-minute long oculopression with a subsequent 
rise of IOP during the recovery period. This finding supports our 
hypothesis, that the new oculopression technique could be used 
as an indirect measurement of aqueous outflow facility. 
 
• The extent of the initial IOP reduction after oculopression (PR0-
P0) varied among the studied groups. 
 
• Healthy subjects showed the largest IOP reduction after 
oculopression (PR0-P0) and their results were statistically 
significantly different in comparison to non-operated glaucoma 
patients. 
 
• The IOP curve of glaucoma patients after XEN Stent or iStent 
inject implantation approximated that one of healthy subjects, 
suggesting that these intraocular implants had positively 




• Patients after MIGS surgery benefited from a relatively low 
complication profile and a significant reduction in the topically 
applied antiglaucoma medication. 
 
• In future studies, the new oculopression technique can be used 
to reveal differences between individual MIGS techniques. In 
order to do that, a larger number of patients must be examined, 
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